Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SKRR Exploration Inc. V.SKRR

Alternate Symbol(s):  SKKRF

SKRR Exploration Inc. is a Canada-based precious metal explorer with properties in Saskatchewan mining jurisdictions. The Company's primary exploration focus is its three gold properties on the Trans-Hudson Corridor in Saskatchewan. The Company’s projects include Nickel Peak Group, Carp River, Manson Bay, Father Lake, Irving, Olson, Ithingo and Cathro. The Carp River property, comprised of five contiguous mineral claims totaling 5,606.48 hectares (ha), is located immediately north of the hamlet of Stony Rapids in the province of Saskatchewan. The 4,293 ha Manson Bay Project is located 40 kilometers (Km) northwest of Flin Flon, Manitoba’s historic mining center and four kilometers southwest of the Schotts Lake Copper-Zinc Deposit in Saskatchewan. The Father Lake property is located 40 km northeast of the hamlet of Stony Rapids in the province of Saskatchewan. The Ithingo Project consists of 12 contiguous mineral claims comprising an overall land package of approximately 2,849 hectares.


TSXV:SKRR - Post by User

Bullboard Posts
Post by DCArnoldon May 19, 2001 11:38pm
347 Views
Post# 3764569

Article in Barron's

Article in Barron'sHealth, biotech firms target cancer By CBS.MarketWatch.com Last Update: 1:11 PM ET May 19, 2001 WASHINGTON (CBS.MW) -- Biotechnology companies and drug makers developing cancer treatments stand to benefit immensely from new breakthroughs in science and genomics, according to a Barron's article Saturday. Bristol-Myers Squibb (BMY: news, msgs, alerts) , the pharmaceutical leader in oncology, is spending millions on genomic research to find new ways to battle the cancer cell. AstraZeneca (AZN: news, msgs, alerts) , Biomira (BIOM: news, msgs, alerts) and Onyx Pharmaceuticals (ONXX: news, msgs, alerts) are also working on anti-cancer vaccines and compounds. EntreMed (ENMD: news, msgs, alerts) and Genentech (DNA: news, msgs, alerts ) are among 20 companies with anti-angiogenic drugs under development. These treatments seek to stop cancer by cutting off the blood supply to tumors. Researchers at OSI Pharmaceuticals, ILEX Oncology (ILXO: news, msgs, alerts) , Pharmacyclics (PCYC: news, msgs, alerts) , MGI Pharma (MOGN: news, msgs, alerts) , SuperGen (SUPG: news, msgs, alerts) , and Tularik (TLRK: news, msgs, alerts) are working on advanced chemotherapy products. While the incidence rate of heart disease, the country's biggest killer, is declining, the incidence of cancer is still rising. More than 1.2 million Americans will be diagnosed with the disease this year.
Bullboard Posts